Compare Procter & Gamble Health with Natco Pharma - Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

PROCTER & GAMBLE HEALTH vs NATCO PHARMA - Comparison Results

PROCTER & GAMBLE HEALTH     Change

Merck, the Indian arm of Merck KgaA (Germany), is a relatively smaller player among MNC pharma majors in the country. Merck has two business segments namely Pharmaceuticals and Chemicals. The pharmaceutical business, accounting for 68% of total sales... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    PROCTER & GAMBLE HEALTH NATCO PHARMA PROCTER & GAMBLE HEALTH/
NATCO PHARMA
 
P/E (TTM) x 40.4 17.7 228.8% View Chart
P/BV x 4.2 2.8 149.5% View Chart
Dividend Yield % 11.4 1.2 939.8%  

Financials

 PROCTER & GAMBLE HEALTH   NATCO PHARMA
EQUITY SHARE DATA
    PROCTER & GAMBLE HEALTH
Dec-18
NATCO PHARMA
Mar-19
PROCTER & GAMBLE HEALTH/
NATCO PHARMA
5-Yr Chart
Click to enlarge
High Rs3,549849 418.0%   
Low Rs1,301557 233.6%   
Sales per share (Unadj.) Rs511.4573.8 89.1%  
Earnings per share (Unadj.) Rs61.3176.0 34.8%  
Cash flow per share (Unadj.) Rs74.0198.2 37.3%  
Dividends per share (Unadj.) Rs440.006.25 7,040.0%  
Dividend yield (eoy) %18.10.9 2,040.7%  
Book value per share (Unadj.) Rs927.8842.7 110.1%  
Shares outstanding (eoy) m16.6036.50 45.5%   
Bonus/Rights/Conversions -BB-  
Price / Sales ratio x4.71.2 387.1%   
Avg P/E ratio x39.64.0 990.6%  
P/CF ratio (eoy) x32.83.5 923.8%  
Price / Book Value ratio x2.60.8 313.4%  
Dividend payout %717.93.6 20,216.3%   
Avg Mkt Cap Rs m40,25725,660 156.9%   
No. of employees `0001.15.0 22.9%   
Total wages/salary Rs m1,3133,559 36.9%   
Avg. sales/employee Rs Th7,486.74,225.3 177.2%   
Avg. wages/employee Rs Th1,157.6718.0 161.2%   
Avg. net profit/employee Rs Th897.21,295.9 69.2%   
INCOME DATA
Net Sales Rs m8,49020,945 40.5%  
Other income Rs m2441,302 18.7%   
Total revenues Rs m8,73422,247 39.3%   
Gross profit Rs m1,4827,948 18.6%  
Depreciation Rs m211810 26.1%   
Interest Rs m0193 0.0%   
Profit before tax Rs m1,5148,247 18.4%   
Minority Interest Rs m00-   
Prior Period Items Rs m00-   
Extraordinary Inc (Exp) Rs m660-   
Tax Rs m5631,823 30.9%   
Profit after tax Rs m1,0176,424 15.8%  
Gross profit margin %17.537.9 46.0%  
Effective tax rate %37.122.1 168.0%   
Net profit margin %12.030.7 39.1%  
BALANCE SHEET DATA
Current assets Rs m15,34323,472 65.4%   
Current liabilities Rs m1,9607,287 26.9%   
Net working cap to sales %157.677.3 204.0%  
Current ratio x7.83.2 243.0%  
Inventory Days Days4992 52.9%  
Debtors Days Days2888 32.2%  
Net fixed assets Rs m1,20918,648 6.5%   
Share capital Rs m166365 45.5%   
"Free" reserves Rs m15,23534,525 44.1%   
Net worth Rs m15,40130,760 50.1%   
Long term debt Rs m00-   
Total assets Rs m17,59543,031 40.9%  
Interest coverage xNM43.7-  
Debt to equity ratio x00-  
Sales to assets ratio x0.50.5 99.1%   
Return on assets %5.815.4 37.6%  
Return on equity %6.620.9 31.6%  
Return on capital %10.327.4 37.4%  
Exports to sales %00-   
Imports to sales %00-   
Exports (fob) Rs mNANA-   
Imports (cif) Rs mNANA-   
Fx inflow Rs m1,63611,536 14.2%   
Fx outflow Rs m4,3682,939 148.6%   
Net fx Rs m-2,7328,597 -31.8%   
CASH FLOW
From Operations Rs m-1,3046,688 -19.5%  
From Investments Rs m12,697-6,122 -207.4%  
From Financial Activity Rs m-301-509 59.0%  
Net Cashflow Rs m11,09366 16,807.4%  

Share Holding

Indian Promoters % 0.0 52.0 -  
Foreign collaborators % 51.8 1.5 3,523.8%  
Indian inst/Mut Fund % 18.2 7.8 232.1%  
FIIs % 1.0 16.6 6.0%  
ADR/GDR % 0.0 0.0 -  
Free float % 29.1 26.0 111.9%  
Shareholders   28,591 25,395 112.6%  
Pledged promoter(s) holding % 0.0 0.0 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare PROCTER & GAMBLE HEALTH With:   FDC LTD.  UNICHEM LAB  WYETH LTD  AJANTA PHARMA  ALEMBIC LTD  

Compare PROCTER & GAMBLE HEALTH With:   ADCOCK INGRAM (S. Africa)  MYLAN (US)  ACTAVIS (US)  TEVA PHARMA (Israel)  



Today's Market

Sensex Ends 674 Points Lower; Banking and Finance Stocks Witness Selling(Closing)

Indian share markets witnessed selling pressure throughout the day and ended lower. Investors were worried about the economic impact and uncertainty over the coronavirus pandemic.

Related Views on News

NATCO PHARMA Announces Quarterly Results (3QFY20); Net Profit Down 34.5% (Quarterly Result Update)

Feb 17, 2020 | Updated on Feb 17, 2020

For the quarter ended December 2019, NATCO PHARMA has posted a net profit of Rs 1 bn (down 34.5% YoY). Sales on the other hand came in at Rs 5 bn (down 13.4% YoY). Read on for a complete analysis of NATCO PHARMA's quarterly results.

PROCTER & GAMBLE HEALTH Announces Quarterly Results (2QFY20); Net Profit Down 13.0% (Quarterly Result Update)

Nov 14, 2019 | Updated on Nov 14, 2019

For the quarter ended September 2019, PROCTER & GAMBLE HEALTH has posted a net profit of Rs 358 m (down 13.0% YoY). Sales on the other hand came in at Rs 2 bn (down 0.4% YoY). Read on for a complete analysis of PROCTER & GAMBLE HEALTH's quarterly results.

PROCTER & GAMBLE HEALTH Announces Quarterly Results (1QFY20); Net Profit Up 34.3% (Quarterly Result Update)

Aug 13, 2019 | Updated on Aug 13, 2019

For the quarter ended June 2019, PROCTER & GAMBLE HEALTH has posted a net profit of Rs 441 m (up 34.3% YoY). Sales on the other hand came in at Rs 2 bn (up 6.1% YoY). Read on for a complete analysis of PROCTER & GAMBLE HEALTH's quarterly results.

NATCO PHARMA Announces Quarterly Results (1QFY20); Net Profit Down 21.1% (Quarterly Result Update)

Aug 13, 2019 | Updated on Aug 13, 2019

For the quarter ended June 2019, NATCO PHARMA has posted a net profit of Rs 1 bn (down 21.1% YoY). Sales on the other hand came in at Rs 5 bn (down 8.6% YoY). Read on for a complete analysis of NATCO PHARMA's quarterly results.

PROCTER & GAMBLE HEALTH 2017-18 Annual Report Analysis (Annual Result Update)

Aug 8, 2019 | Updated on Aug 8, 2019

Here's an analysis of the annual report of PROCTER & GAMBLE HEALTH for 2017-18. It includes a full income statement, balance sheet and cash flow analysis of PROCTER & GAMBLE HEALTH. Also includes updates on the valuation of PROCTER & GAMBLE HEALTH.

More Views on News

Most Popular

Sorry Warren Buffett, I'm Following This Man Instead of You in 2020(The 5 Minute Wrapup)

Mar 30, 2020

This man warned of an impending market correction while everyone else was celebrating the renewed optimism in early 2020...

The Biggest Trading Opportunity of 2020 is Here...

Mar 26, 2020

India's #1 trader, Vijay Bhambwani, talks about a hugely profitable trading opportunity which you must know about today!

A Big Trading Opportunity is Coming Your Way Soon(Fast Profits Daily)

Mar 25, 2020

I see a big opportunity to make fast profits on the horizon.

Coronavirus Sell-off Is a Perfect Time to 'Lockdown' this 'Crorepati' Stock(Profit Hunter)

Mar 24, 2020

Coronavirus crisis and panic selling has brought this quality smallcap to multiyear lows, making it a great bargain.

Lockdown! Now the Bailout...(The Honest Truth)

Mar 25, 2020

Ajit Dayal on what India should do to manage the coronavirus impact on the economy.

More

How to Trade the
Coronavirus Crash

Coronavirus Crash
Get this special report, authored by Equitymaster's top analysts, now.
We will never sell or rent your email id.
Please read our Terms

PROCTER & GAMBLE HEALTH SHARE PRICE


Apr 3, 2020 (Close)

TRACK PROCTER & GAMBLE HEALTH

  • Track your investment in PROCTER & GAMBLE HEALTH with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

MORE ON PROCTER & GAMBLE HEALTH

PROCTER & GAMBLE HEALTH 5-YR ANALYSIS

COMPARE PROCTER & GAMBLE HEALTH WITH

MARKET STATS